Frontiers in Immunology | Cancer Immunity and Immunotherapy

Original Research

Published on 03 Dec 2024

Identification of SPP1+ macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics

in Cancer Immunity and Immunotherapy

Han Jin
Woonghee Kim
Meng Yuan
Xiangyu Li
Hong Yang
Mengzhen Li
Mengnan Shi
Hasan Turkez
Mathias Uhlen
Cheng Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1446453

2,523 views

Original Research

Published on 02 Dec 2024

Cryoablation of primary breast cancer tumors induces a systemic abscopal effect altering TIME (Tumor Immune Microenvironment) in distant tumors

in Cancer Immunity and Immunotherapy

Flávia Sardela de Miranda
Dalia Martinez-Marin
Rachel L. Babcock
Maribel Castro
Geetha P. Boligala
Sonia Y. Khan
Kathryn L. Furr
Isabel Castro-Piedras
Nicholas Wagner
Dakota E. Robison

Frontiers in Immunology

doi 10.3389/fimmu.2024.1498942

2,063 views

Original Research

Published on 02 Dec 2024

Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma

in Cancer Immunity and Immunotherapy

Jing Ruan
Daobin Zhou
Yan Zhang
Danqing Zhao
Chong Wei
Ke Hu
Fuquan Zhang
Xiaorong Hou
Wei Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1481080

1,241 views

Original Research

Published on 02 Dec 2024

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma

in Cancer Immunity and Immunotherapy

Saima Jamil Farooqi
Zhi Zhao
Åsa Kristina Öjlert
Solfrid Thunold
Hedvig Vidarsdotter Juul
Maria Moksnes Bjaanæs
Henrik Horndalsveen
Hanne Marte Gjertsen Nymoen
Åslaug Helland
Vilde Drageset Haakensen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1480183

1,627 views

Clinical Trial

Published on 02 Dec 2024

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

in Cancer Immunity and Immunotherapy

Na Zhou
Yuwei Hua
Yuping Ge
Qiang Wang
Chenyu Wang
Jia He
Luo Zhao
Shuangni Yu
Junfang Yan
Lin Zhao

Frontiers in Immunology

doi 10.3389/fimmu.2024.1482005

1,247 views

Case Report

Published on 02 Dec 2024

Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports

in Cancer Immunity and Immunotherapy

Kevin Y. Li
Andrew M. Lowy
Paul Fanta

Frontiers in Immunology

doi 10.3389/fimmu.2024.1452543

803 views
1 citation

Original Research

Published on 02 Dec 2024

Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics

in Cancer Immunity and Immunotherapy

Yujing Shi
Wantong Zhao
Yuanjian Ding
Xiaolin Ge
Mengyang Ju

Frontiers in Immunology

doi 10.3389/fimmu.2024.1467098

1,387 views

Editorial

Published on 02 Dec 2024

Editorial: Immune cell exhaustion: new challenges and opportunities in cancer therapy

in Cancer Immunity and Immunotherapy

Hao Chi
Lai Jiang
Xuancheng Zhou
Lexin Wang
Guanhu Yang
Honghao Luo
Xiaoli Liu
Ke Xu
Gang Tian

Frontiers in Immunology

doi 10.3389/fimmu.2024.1527428

574 views

Review

Published on 02 Dec 2024

Targeting extracellular matrix stiffness for cancer therapy

in Cancer Immunity and Immunotherapy

Xiuqin Feng
Fujun Cao
Xiangji Wu
Wenyan Xie
Ping Wang
Hong Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1467602

1,924 views

Review

Published on 02 Dec 2024

Harnessing m1A modification: a new frontier in cancer immunotherapy

in Cancer Immunity and Immunotherapy

Xinru Wang
Xiaoqing Ma
Siyu Chen
Minyan Fan
Chenying Jin
Yushi Chen
Shaodong Wang
Zhiying Wang
Fei Meng
Chengwan Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1517604

1,367 views

Original Research

Published on 02 Dec 2024

Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer

in Cancer Immunity and Immunotherapy

Lirui Han
Hankai Yang
Xuan Jiang
Ziyu Zhou
Chang Ge
Kairan Yu
Guofang Li
Wei Wang
Yubo Liu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1512203

1,158 views

Original Research

Published on 02 Dec 2024

PCDHGA10 as a potential prognostic biomarker and correlated with immune infiltration in gastric cancer

in Cancer Immunity and Immunotherapy

Mingyang Zhong
Zhuoqun Yu
Qianqian Wu
Bing Lu
PingPing Sun
Xiaojing Zhang
Lei Yang
Han Wu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1500478

1,215 views

Original Research

Published on 02 Dec 2024

Myeloid response evaluated by noninvasive CT imaging predicts post-surgical survival and immune checkpoint therapy benefits in patients with hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Kangqiang Peng
Xiao Zhang
Zhongliang Li
Yongchun Wang
Hong-Wei Sun
Wei Zhao
Jielin Pan
Xiao-Yang Zhang
Xiaoling Wu
Xiangrong Yu

Frontiers in Immunology

doi 10.3389/fimmu.2024.1493735

1,088 views

Original Research

Published on 02 Dec 2024

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment

in Cancer Immunity and Immunotherapy

Eleonora Sosa Cuevas
Stéphane Mouret
Guillaume Vayssière
Siham Kerboua
Pauline Girard
Jean-Paul Molens
Marc Manceau
Julie Charles
Philippe Saas
Caroline Aspord

Frontiers in Immunology

doi 10.3389/fimmu.2024.1507938

1,132 views

Original Research

Published on 02 Dec 2024

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1

in Cancer Immunity and Immunotherapy

Lvyun Zhu
Ying Qu
Junru Yang
Tong Shao
Jingyu Kuang
Chuanyang Liu
Yanhua Qi
Ming Li
Yingying Li
Sujuan Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1486888

1,047 views

Review

Published on 29 Nov 2024

IL-17A in gastric carcinogenesis: good or bad?

in Cancer Immunity and Immunotherapy

Weidong Li
Xiaodong Huang
Xiaowen Han
Jiayi Zhang
Lei Gao
Hao Chen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1501293

1,186 views
2 citations

Navigation group

Articles

Identification of SPP1+ macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics

Cryoablation of primary breast cancer tumors induces a systemic abscopal effect altering TIME (Tumor Immune Microenvironment) in distant tumors

Hyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma

Serum cytokines as a biomarker for immune checkpoint inhibitor toxicity in patients with pleural mesothelioma

Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study

Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports

Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics

Editorial: Immune cell exhaustion: new challenges and opportunities in cancer therapy

Targeting extracellular matrix stiffness for cancer therapy

Harnessing m1A modification: a new frontier in cancer immunotherapy

Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer

PCDHGA10 as a potential prognostic biomarker and correlated with immune infiltration in gastric cancer

Myeloid response evaluated by noninvasive CT imaging predicts post-surgical survival and immune checkpoint therapy benefits in patients with hepatocellular carcinoma

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1

IL-17A in gastric carcinogenesis: good or bad?